Masscure Medicines Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 11-07-2024
- Paid Up Capital ₹ 0.10 M
as on 11-07-2024
- Company Age 5 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 392.70%
(FY 2021)
- Profit 304.27%
(FY 2021)
- Ebitda 376.64%
(FY 2021)
- Net Worth 2072.40%
(FY 2021)
- Total Assets 95.63%
(FY 2021)
About Masscure Medicines
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Abhijeet Shetti, Masum Makandar, Abhijit Asalkar, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24239PN2019PTC185155
- Company No.
185155
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Jul 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Kolhapur, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Masscure Medicines?
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abhijeet Shetti  | Director | 01-Dec-2021 | Current |
| Masum Makandar | Director | 01-Dec-2021 | Current |
| Abhijit Asalkar | Director | 30-Jan-2020 | Current |
| Pooja Asalkar | Director | 30-Jan-2020 | Current |
| Priti Shetti | Director | 01-Jul-2019 | Current |
| Rashida Makandar | Director | 01-Jul-2019 | Current |
Financial Performance of Masscure Medicines.
Masscure Medicines Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 392.7% increase. The company also saw a substantial improvement in profitability, with a 304.27% increase in profit. The company's net worth Soared by an impressive increase of 2072.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Masscure Medicines?
In 2021, Masscure Medicines had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Promasscure Medicines Private LimitedActive 1 year 3 months
Masum Makandar and Rashida Makandar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Masscure Medicines?
Unlock and access historical data on people associated with Masscure Medicines, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Masscure Medicines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Masscure Medicines's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
